What changed is that Novo Nordisk increased production of brand-name Wegovy and Ozempic, which reduced some supply pressure
Retatrutide Retatrutide represents another approach to multi-pathway activation, functioning as a triple agonist (GIP/GLP-1/glucagon) in a single molecule: Cagrilintide + GLP-1 Approach: Two separate injections Amylin + GLP-1 pathways Established safety profile for each component Flexible dose adjustment of each component Retatrutide Approach: Single injection GIP + GLP-1 + Glucagon pathways Novel triple mechanism in one molecule Fixed ratio of pathway activation Both approaches show promise for significant metabolic benefits, though they achieve multi-pathway activation through different strategies
10.1210/jc.2003-031907 53
Patients with a history of chronic pancreatitis, pancreatic cancer, or other significant pancreatic disorders may not be suitable candidates for this therapy
Stradaioli G, Sylla L, Zelli R, Chiodi P, Monaci M
One obvious impact of consumers using GLP-1 is that they eat and spend less: grocery spending declines of about 6% for the general population and of 9% for the high-end consumers, which are the ones that brands tend to focus on